Christian Mandl
Founder at Tiba Biotech LLC
Profile
Christian W.
Mandl, Ph.D., M.D.
is a Senior Advisor to Adjuvant Capital, and he provides consulting services to industry partners and non-profit organizations around the world for vaccine and viral vector programs.
Previously he was the Senior Vice President of Research for VIR Biotechnology (San Francisco, CA).
Until 2015, he was Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines.
Prior to joining Novartis in 2008, Christian was Professor and Assistant Head of the Clinical Institute of Virology at Medical University of Vienna.
His academic research focused on molecular mechanisms of RNA viruses, their interactions with host organisms targeting novel medical applications, enabling new antiviral strategies and applications in vaccine development or viral gene vectors.
He is a world-renowned expert in the molecular biology of flaviviruses and RNA vaccines.
He has authored more than 100 scientific publications, and is an inventor on patents related to a marketed tick-borne encephalitis (flavivirus) vaccine, the SAM technology, and other antiviral approaches.
Christian holds a PhD and MD from University of Vienna, and a Master of Science (Biochemistry) from Pennsylvania State University.
He earned his postdoctoral lecturer qualification (Habilitation) in Molecular Virology and was certified as a Medical Specialist in Virology by the Austrian Medical Association.
His engagement with the health care industry and public health organizations includes roles as a Co-founder and Chair, Scientific Advisory Board for Tiba Biotech (Cambridge, MA), Chair, Scientific Advisory Board for Themis Biotech (Vienna, Austria), and Chair, Scientific Advisory Group for the International Vaccine Institute (Seoul, Korea).
Christian Mandl active positions
Companies | Position | Start |
---|---|---|
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Consultant / Advisor | 2019-08-31 |
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Founder | 2018-02-28 |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Consultant / Advisor | 2018-08-31 |
Former positions of Christian Mandl
Companies | Position | End |
---|---|---|
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Chairman | 2020-05-31 |
VIR BIOTECHNOLOGY, INC. | Private Equity Investor | 2017-12-30 |
NOVARTIS AG | Private Equity Investor | 2014-04-29 |
Medical University of Vienna | Corporate Officer/Principal | 2008-03-31 |
Training of Christian Mandl
The Pennsylvania State University | Graduate Degree |
University of Vienna | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
NOVARTIS AG | Health Technology |
VIR BIOTECHNOLOGY, INC. | Health Technology |
Private companies | 4 |
---|---|
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Commercial Services |
Themis Bioscience GmbH
Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Health Technology |
Adjuvant Capital LP
Adjuvant Capital LP Investment ManagersFinance Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York. | Finance |
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Health Technology |
- Stock Market
- Insiders
- Christian Mandl